Akinetic mutism (AM) is a rare neurological syndrome characterized by the complete or near-complete absence of spontaneous movement (akinesia) and speech (mutism) with preserved consciousness and sensorimotor capacity. [1-2] Patients appear awake but profoundly apathetic, seemingly indifferent to pain, thirst, or hunger. It represents the extreme end of the spectrum of disorders of diminished motivation (apathy → abulia → akinetic mutism). [1]
The underlying pathophysiology involves disruption of frontal-subcortical circuits, particularly the medial prefrontal cortex, anterior cingulate cortex, caudate nucleus, thalamus, and mesencephalic structures that drive goal-directed behavior. [1][3]
1. History
- Onset and tempo: Acute (stroke, hemorrhage) vs. subacute (hydrocephalus, tumor, infection) vs. post-surgical
- Preceding events: Recent neurosurgery (especially AComA aneurysm clipping/coiling), head trauma, cardiac arrest, respiratory arrest, ICU stay
- Baseline function: Pre-morbid cognitive and functional status
- Progression: Sudden loss of speech and movement vs. gradual decline in spontaneity
- Associated symptoms: Was the patient initially comatose? Did consciousness return but behavior did not?
- Important negatives: No paralysis, no aphasia (when speech does occur it is grammatically correct), no apparent sensory loss [4]
2. Alarm Features
- Acute onset suggesting stroke (especially bilateral ACA territory, thalamic, or mesencephalic infarction) [5-7]
- Signs of elevated intracranial pressure (headache, papilledema, vomiting) — may indicate obstructive hydrocephalus or mass lesion [8-9]
- Fever + rigidity — consider neuroleptic malignant syndrome or CNS infection [10-11]
- Rapidly progressive course — consider Creutzfeldt-Jakob disease, autoimmune encephalitis, or status epilepticus
- Post-cardiac arrest or hypoxic event — delayed post-hypoxic leukoencephalopathy [12]
- Recent COVID-19 with severe respiratory illness or meningoencephalitis [13-14]
3. Medications
Medications that may contribute
- Dopamine-blocking agents (antipsychotics) — can worsen or precipitate akinetic states [10]
- Sedatives, anticonvulsants at supratherapeutic levels
- Serotonergic agents (consider serotonin syndrome in the differential)
Treatments used in AM (all off-label, evidence limited to case reports/series):
- Dopaminergic agents (first-line pharmacologic approach):
- Carbidopa/levodopa [15]
- Bromocriptine (with or without ephedrine) [8]
- Amantadine [16]
- Stimulants: Methylphenidate, modafinil [2][17]
- Atomoxetine (selective NE reuptake inhibitor) — case report showing improvement in chronic AM [18]
- IV magnesium sulfate — reported in delayed post-hypoxic leukoencephalopathy [12]
Key distinction: Unlike catatonia, AM does not typically respond to benzodiazepines. [13-14] A negative lorazepam challenge can help differentiate AM from catatonia.
4. Diet
- Not a primary management consideration
- Patients are often unable to self-feed due to lack of volitional initiation — enteral nutrition (NG/PEG tube) is frequently required
- Aspiration risk assessment is critical before any oral intake
- Adequate hydration and nutritional support are essential during the akinetic phase
5. Review of Systems
- Neurologic: Spontaneous eye opening/tracking, response to pain, any vocalizations, bowel/bladder function
- Psychiatric: History of psychotic disorders, mood disorders, catatonic episodes
- Infectious: Fever, recent illness (especially COVID-19), meningeal signs [13-14]
- Cardiovascular: Embolic sources (cardiac valvular disease, arrhythmia) [2]
- Endocrine: Thyroid function (myxedema coma can mimic)
- Toxicologic: Carbon monoxide exposure, drug overdose [12][19]
6. Collateral History and Family History
- Critical to obtain — the patient cannot provide history
- Pre-morbid personality, baseline cognitive function, psychiatric history
- Medication list (especially antipsychotics, sedatives)
- Substance use history (alcohol, drugs, carbon monoxide exposure)
- Timeline of symptom onset as observed by family/caregivers
- Family history of stroke, hypercoagulable states, neurodegenerative disease
- Social context: living situation, advance directives, goals of care
7. Risk Factors
- Cerebrovascular disease: Hypertension, atrial fibrillation, diabetes, smoking, hypercoagulable states [2]
- Anterior communicating artery (AComA) aneurysm rupture/surgery — classic association due to bilateral ACA territory involvement [18][20]
- Bilateral frontal or mesencephalic lesions of any etiology [1][7]
- Hydrocephalus (especially obstructive) [8-9]
- Severe systemic illness: COVID-19 with severe respiratory failure or meningoencephalitis [13-14]
- Hypoxic-ischemic injury (cardiac arrest, near-drowning, CO poisoning) [12][19]
- Pre-existing neuropsychiatric vulnerability [14]
8. Differential Diagnosis
Critical pearl: C. Miller Fisher described AM as a "pure motor catatonia" — it lacks the affective (fear) and behavioral (stereotypies, mannerisms) features of catatonia. [13] The lorazepam challenge is the most practical bedside differentiator: catatonia responds; AM does not. [13-14]
9. Past Medical History
- Prior stroke or TIA (especially bilateral)
- Neurosurgical history (AComA aneurysm repair, tumor resection, VP shunt)
- History of hydrocephalus or shunt malfunction [8]
- Cardiac disease (valvular disease, arrhythmia — embolic source) [2]
- Psychiatric history (schizophrenia, mood disorders, prior catatonic episodes)
- History of cardiac arrest or prolonged hypoxia
- Autoimmune or inflammatory conditions
10. Physical Exam
Vital signs: Fever (infection, NMS), hypertension (stroke), autonomic instability
Neurologic exam — key findings
- Eyes open spontaneously — distinguishes from coma [1]
- Visual tracking may be present — distinguishes from vegetative state [4]
- Absence of spontaneous movement and speech despite intact motor pathways
- Normal muscle tone (vs. rigidity in NMS/parkinsonism, waxy flexibility in catatonia)
- Withdrawal to pain may be present — sensorimotor pathways intact [9]
- Cranial nerves intact; no gaze palsy (vs. locked-in syndrome with horizontal gaze palsy)
- No catalepsy, posturing, or echophenomena (vs. catatonia) [24]
- Assess for signs of hydrocephalus: gait apraxia, incontinence, upgaze palsy
Focused maneuvers
- Bush-Francis Catatonia Rating Scale to formally assess for catatonia [11]
- Coma Recovery Scale-Revised (CRS-R) if concern for disorder of consciousness [25]
11. Lab Studies
- CBC, CMP, LFTs, TSH — rule out metabolic/endocrine causes
- CK — elevated in NMS
- Ammonia — hepatic encephalopathy
- Toxicology screen — drug-induced states
- Carboxyhemoglobin — if CO exposure suspected [19]
- ESR, CRP, procalcitonin — infectious/inflammatory etiologies
- Blood cultures, CSF analysis — if meningitis/encephalitis suspected
- Autoimmune encephalitis panel (anti-NMDA receptor antibodies, LGI1, CASPR2) — if subacute onset
- Coagulation studies, hypercoagulability workup — if stroke etiology [2]
- D-dimer, ferritin, LDH — if post-COVID-19 [13]
12. Imaging
First-line
Gold standard
- MRI brain with DWI — identifies ischemic infarction (especially bilateral ACA, thalamic, mesencephalic territories), white matter disease, tumors [2][5]
- Key areas to evaluate: anterior cingulate cortex, medial prefrontal cortex, caudate, thalamus, mesencephalon [1][3]
Advanced imaging (when available)
- Diffusion tensor tractography (DTT) — can evaluate prefronto-caudate and prefronto-thalamic tract integrity; helps differentiate AM from disorders of consciousness [3][25]
- FDG-PET — shows decreased frontal/cingulate metabolism [18-19]
- SPECT — can reveal bifrontal hypoperfusion even without structural lesion [26]
- CT/MR angiography — evaluate for vascular occlusion or aneurysm
When imaging may be unnecessary: If etiology is already established (e.g., known post-surgical bilateral frontal injury) and clinical course is stable.
13. Special Tests
- Lorazepam challenge test: 1–2 mg IV lorazepam — response supports catatonia; lack of response favors AM [11][13]
- Bush-Francis Catatonia Rating Scale (BFCRS): Standardized assessment; AM patients typically score on mutism/stupor items but lack catalepsy, waxy flexibility, echophenomena [11]
- Coma Recovery Scale-Revised (CRS-R): Helps differentiate AM from disorders of consciousness; AM patients may achieve full scores on arousal subscale [25]
- Continuous EEG monitoring: Rule out non-convulsive status epilepticus; may show BIPLEDs in bilateral ACA infarction; background may be disorganized but reactive [6]
- TMS-EEG (research): Can demonstrate preserved cortical complexity consistent with consciousness despite behavioral unresponsiveness [21]
14. ECG
- Indicated to evaluate for cardiac embolic sources (atrial fibrillation, valvular disease) [2]
- Prolonged telemetry or Holter monitoring if paroxysmal arrhythmia suspected
- Echocardiography (TTE/TEE) should be considered if embolic stroke is the etiology — may reveal valvular masses (e.g., papillary fibroelastoma) [2]
- No specific ECG pattern is diagnostic of AM itself
15. Assessment
AM is a clinical diagnosis based on the triad of: (1) absence of spontaneous speech, (2) absence of spontaneous movement, and (3) preserved wakefulness/consciousness. [1] It results from disruption of frontal-subcortical motivational circuits rather than motor or language pathways.
Severity stratification
- Complete AM: No spontaneous speech or movement
- Partial AM / abulia: Reduced but not absent volitional behavior (exists on a spectrum) [15][24]
Typical vs. atypical presentations
- Typical: Post-AComA aneurysm rupture/repair with bilateral frontal injury
- Atypical: Cerebellar stroke causing frontal diaschisis; COVID-19-associated AM; delayed post-hypoxic leukoencephalopathy [12][14][26]
Complications: Aspiration pneumonia, DVT/PE, pressure injuries, malnutrition, contractures, urinary tract infections — all consequences of prolonged immobility.
16. Treatment Plan
Initial stabilization
- ABCs; secure airway if needed
- Treat underlying etiology (e.g., EVD for hydrocephalus, antibiotics for infection, anticoagulation for embolic stroke)
- DVT prophylaxis, skin care, nutritional support
Pharmacologic management (evidence limited to case reports/series):
- Dopaminergic agents are the mainstay:
- Carbidopa/levodopa 25/100 mg TID, titrate as tolerated [15]
- Bromocriptine 2.5 mg BID–TID, titrate up [8]
- Amantadine 100 mg BID (also has NMDA antagonist properties) [16]
- Stimulants if dopaminergic agents insufficient:
- Methylphenidate 5–10 mg BID (morning and noon)
- Modafinil 100–200 mg daily
- Atomoxetine 40–80 mg daily — noradrenergic mechanism [18]
- Lorazepam challenge should be attempted to rule out catatonia; if positive, treat as catatonia with scheduled lorazepam [11]
Non-pharmacologic
- Intensive multidisciplinary rehabilitation (PT, OT, SLP) [2][20]
- Structured sensory stimulation
- VP shunt revision if hydrocephalus is contributing [8][20]
17. Disposition
Admission criteria
- All new-onset AM requires inpatient evaluation
- ICU if acute stroke, elevated ICP, or hemodynamic instability
- Neurology and/or neurosurgery consultation
Observation indications
Specialist consultation triggers
- Neurology — all cases
- Neurosurgery — hydrocephalus, mass lesion, aneurysm
- Psychiatry — to differentiate from catatonia; lorazepam challenge interpretation [11][13]
- Neurorehabilitation — once medically stable [2][20]
Discharge criteria
- Underlying etiology treated or stabilized
- Pharmacologic trial initiated with monitoring plan
- Safe disposition to rehabilitation facility with appropriate level of care
18. Follow Up / Return Precautions
Expected recovery course
- AM duration is variable; COVID-19-associated AM typically lasts 1–2 weeks [13]
- Post-stroke or post-surgical AM may persist for weeks to months; some patients show gradual improvement with dopaminergic therapy and rehabilitation [15][20]
- An apathetic/abulic state may persist even after akinesia resolves [15]
Follow-up timing
- Neurology follow-up within 1–2 weeks of discharge
- Repeat neuroimaging as clinically indicated
- Medication titration and response monitoring
Symptoms requiring immediate reassessment
- New focal neurologic deficits (recurrent stroke)
- Fever, aspiration, respiratory distress
- Seizures
- Worsening level of consciousness (may indicate new pathology, not just AM)
Patient/family counseling
- AM is a disorder of motivation, not consciousness — the patient is aware but unable to initiate action [1]
- Recovery is possible, especially with treatment of reversible etiologies and dopaminergic therapy [15]
- Rehabilitation is a critical component of recovery [2][20]
- Advance care planning discussions should be initiated early given prognostic uncertainty
Images
References
1. On the Pathophysiology and Treatment of Akinetic Mutism. — Arnts H, van Erp WS, Lavrijsen JCM, et al. Neuroscience and Biobehavioral Reviews. 2020.
2. Akinetic Mutism Following Bilateral Infarcts Associated With a Mitral Valve Papillary Fibroelastoma. — Lyndon S. Psychopharmacology Bulletin. 2025.
3. A Review of Studies on the Role of Diffusion Tensor Magnetic Resonance Imaging Tractography in the Evaluation of the Fronto-Subcortical Circuit in Patients With Akinetic Mutism. — Jang SH, Byun DH. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2022.
4. Akinetic Mutism and the Story of David. — Sinden R, Wilson BA, Rose A, Mistry N. Neuropsychological Rehabilitation. 2018.
5. Akinetic Mutism Following Stroke. — Nagaratnam N, Nagaratnam K, Ng K, Diu P. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 2004.
6. BIPLEDs in Akinetic Mutism Caused by Bilateral Anterior Cerebral Artery Infarction. — Nicolai J, van Putten MJ, Tavy DL. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2001.
7. Akinetic Mutism and Bilateral Anterior Cerebral Artery Occlusion. — Freemon FR. Journal of Neurology, Neurosurgery, and Psychiatry. 1971.
8. Relief of Akinetic Mutism From Obstructive Hydrocephalus Using Bromocriptine and Ephedrine. Case Report. — Anderson B. Journal of Neurosurgery. 1992.
9. Approach to the Patient in Vegetative State. Part II: Differential Diagnosis. — Latronico N, Antonini L, Taricco M, Vignolo LA, Candiani A. Minerva Anestesiologica. 2000.
10. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
11. Catatonia. — Heckers S, Walther S. The New England Journal of Medicine. 2023.
12. Rapid Resolution of Akinetic Mutism in Delayed Post-Hypoxic Leukoencephalopathy With Intravenous Magnesium Sulfate. — Rozen TD. NeuroRehabilitation. 2012.
13. Resource Document on Acute Neuropsychiatric Sequelae of COVID-19 Infection. — Scott Beach, Nadia Cacodcar, Erica Baller, Jon Levenson American Psychiatric Association (2023). 2023.
14. Akinetic Mutism and Coronavirus Disease 2019: A Narrative Review. — Fusunyan M, Praschan N, Fricchione G, Beach S. Journal of the Academy of Consultation-Liaison Psychiatry. 2021.
15. Chronic Akinetic Mutism After Mesencephalic-Diencephalic Infarction: Remediated With Dopaminergic Medications. — Alexander MP. Neurorehabilitation and Neural Repair. 2002.
16. Pharmacology in Treatment of Patients With Disorders of Consciousness. — Marino MH. Physical Medicine and Rehabilitation Clinics of North America. 2024.
17. Pharmacologic Therapies to Promote Recovery of Consciousness. — Barra ME, Edlow BL, Brophy GM. Seminars in Neurology. 2022.
18. Treatment of Chronic Akinetic Mutism With Atomoxetine: Subtraction Analysis of Brain F-18 Fluorodeoxyglucose Positron Emission Tomographic Images Before and After Medication: A Case Report. — Kim YW, Shin JC, An YS. Clinical Neuropharmacology. 2010.
19. Frontal Lobe and Cingulate Cortical Metabolic Dysfunction in Acquired Akinetic Mutism: A PET Study of the Interval Form of Carbon Monoxide Poisoning. — Tengvar C, Johansson B, Sorensen J. Brain Injury. 2004.
20. Recovery of Akinetic Mutism and Injured Prefronto-Caudate Tract Following Shunt Operation for Hydrocephalus and Rehabilitation: A Case Report. — Jang SH, Chang CH, Jung YJ, Lee HD. Medicine. 2017.
21. Unconsciousness or Unresponsiveness in Akinetic Mutism? Insights From a Multimodal Longitudinal Exploration. — Comanducci A, Casarotto S, Rosanova M, et al. The European Journal of Neuroscience. 2024.
22. Atypical Presentations of Acute Cerebrovascular Syndromes. — Edlow JA, Selim MH. The Lancet. Neurology. 2011.
23. Akinetic Mutism and Mixed Transcortical Aphasia Following Left Thalamo-Mesencephalic Infarction. — Nagaratnam N, McNeil C, Gilhotra JS. Journal of the Neurological Sciences. 1999.
24. Resource Document on Catatonia. — Jo Ellen Wilson, Mark A. Oldham, Andrew Francis, et al American Psychiatric Association (2025). 2025.
25. Differential Diagnosis of Akinetic Mutism and Disorder of Consciousness Using Diffusion Tensor Tractography: A Case Report. — Byun DH, Jang SH. Frontiers in Human Neuroscience. 2022.
26. Akinetic Mutism Without a Structural Prefrontal Lesion. — Demirtas-Tatlidede A, Bahar SZ, Gurvit H. Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology. 2013.